Multimodal characterization of the responsiveness of eight hepatitis D virus genotype isolates to interferon-alpha treatment
Journal of Virology · 2025
DOI: 10.1128/jvi.01280-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, 2025. Verfasst von Yibo Ding und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathogen Biology and Immunology, Jiangsu Key Laboratory of Immunity and Metabolism, Jiangsu International Laboratory of Immunity and Me…. Hauptthemen laut MEDLINE: Hepatitis D, Chronic, Interferon-alpha, Hepatitis Delta Virus, Adenosine Deaminase. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Research Grant of Jiangsu Commission of Health, China, Starting Grant for Talents of Xuzhou Medical University.
Abstract (Originalsprache)
Chronic hepatitis delta virus (HDV) infection causes the most severe form of viral hepatitis. Although humans produce 12 subtypes of interferon-alpha (IFN-α), IFN-α2a has been the only commonly used treatment against HDV. Previously, we characterized eight HDV genotype isolates with varying replication kinetics. Herein, we systematically investigated the antiviral efficacy of IFN-α2a and other IFN-α subtypes against HDV genotypes 1–8 during de novo infection, cell mitosis, and in quiescent cells. Our findings revealed that IFN-α2a exhibits potent but varied efficiency against HDV 1–8 isolates upon de novo infection and cell mitosis. Conversely, HDVs in resting cells are resistant to IFN-α2a treatment and the IFN-containing cytokine cocktail collected from peripheral blood mononuclear cells stimulated with TLR7/8 agonist. Mechanistically, both ADAR1 p110 and p150 promote L-HDAg production and inhibit HDV replication. ADAR1 p150, rather than p110, enhances the anti-HDV efficacy of IFN-α during de novo infection and cell mitosis, but not in resting cells. Moreover, different subtypes of IFN-α exhibit varying anti-HDV activities in both de novo infection and cell mitosis, due to their disparity in activating interferon responses. Among these, IFN-α2a, IFN-α10, and IFN-α14 exhibit the strongest anti-HDV activity and synergize with bulevirtide in suppressing HDV replication. In conclusion, the anti-HDV efficacy of IFN-α depends on multiple factors, including HDV genotypes, ADAR1 p150 level, IFN-α subtypes, and HDV’s different survival strategies. These findings provide valuable implications for the development and optimization of IFN-based therapies. IMPORTANCE Chronic hepatitis delta virus (HDV) infection represents the most severe form of viral hepatitis. This study comprehensively evaluated the antiviral efficacy of interferon-alpha (IFN-α) subtypes across eight HDV genotypes during de novo infection, cell mitosis, or in quiescent cells. Herein, we found that IFN-α exhibits potent but varied efficiency against HDV 1–8 isolates upon de novo infection and cell mitosis. Conversely, HDVs in resting cells are resistant to IFN-α subtypes, regardless of the cellular ADAR1 levels. Among different subtypes, IFN-α2a, IFN-α10, and IFN-α14 exhibit the strongest anti-HDV activity and synergize with bulevirtide in suppressing HDV replication. These findings provide crucial insights into the optimization of IFN-based monotherapy and combinational therapy against chronic HDV infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathogen Biology and Immunology, Jiangsu Key Laboratory of Immunity and Metabolism, Jiangsu International Laboratory of Immunity and Metabolism, Xuzhou Medical University, Xuzhou, China.
- Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
- School of Public Health and Emergency Management, Southern University of Science and Technology, Shenzhen, China.
- Scientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
- Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany.
- German Centre for Infection Research (DZIF) Partner Site Heidelberg, Heidelberg, Germany.
ORCID-Profile: Yibo Ding, Zhenfeng Zhang, Feng Li, Hongbo Guo, Wenshi Wang
Förderung
- National Natural Science Foundation of China
- Research Grant of Jiangsu Commission of Health, China
- Starting Grant for Talents of Xuzhou Medical University
- Natural Science Foundation of Jiangsu Higher Education Institutions of China
- Postgraduate Research & Practice Innovation Program of Jiangsu Province
Zitieren
APA
Ding, Y., Li, Q., Sha, Y., Si, R., Feng, C., Liu, M., Feng, Z., Ding, X., Li, Y., Fu, H., Liang, S., Yao, Q., Zhang, Z., Li, F., Urban, S., Guo, H., & Wang, W. (2025). Multimodal characterization of the responsiveness of eight hepatitis D virus genotype isolates to interferon-alpha treatment. Journal of Virology. https://doi.org/10.1128/jvi.01280-25
Vancouver
Ding Y, Li Q, Sha Y, Si R, Feng C, Liu M, et al. Multimodal characterization of the responsiveness of eight hepatitis D virus genotype isolates to interferon-alpha treatment. Journal of Virology. 2025. doi:10.1128/jvi.01280-25
BibTeX
@article{Ding2025,
author = {Ding, Yibo and Li, Qiudi and Sha, Yunlu and Si, Ruilin and Feng, Chengqian and Liu, Mei and Feng, Zhanghao and Ding, Xutong and Li, Ying and Fu, Huiyuan and Liang, Shiquan and Yao, Qili and Zhang, Zhenfeng and Li, Feng and Urban, Stephan and Guo, Hongbo and Wang, Wenshi},
title = {Multimodal characterization of the responsiveness of eight hepatitis D virus genotype isolates to interferon-alpha treatment},
journal = {Journal of Virology},
year = {2025},
doi = {10.1128/jvi.01280-25}
}
EUVIMED